市場調查報告書
商品編碼
966793

瞼板腺功能障礙 (MGD) - 流行病學考察:2030年

Meibomian Gland Dysfunction - Epidemiology Insight - 2030

出版日期: 按訂單生產 | 出版商: DelveInsight Business Research LLP | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供瞼板腺功能障礙 (MGD) 調查分析,過去、未來的流行病學,以美國、歐洲5個國家 (德國,西班牙,義大利,法國,英國) 、日本的市場趨勢為焦點,提供治療流程、治療指南,流行病學方案相關的系統性資訊。

目錄

第1章 主要考察

第2章 瞼板腺功能障礙 (MGD)的摘要整理

第3章 瞼板腺功能障礙 (MGD) :疾病的背景和概要

  • 簡介
  • 徵兆與症狀
  • 病理生理學
  • 危險因素
  • 診斷

第4章 病人歷程

第5章 流行病學和患者族群

  • 流行病學的主要調查結果
  • 前提條件與根據:主要7個國家
  • 流行病學方案:主要7個國家
  • 美國的流行病學
  • 歐洲5個國家的各國流行病學
  • 日本的流行病學

第6章 治療流程,目前治療,醫療行為

  • 瞼板腺功能障礙 (MGD)的治療與管理
  • 瞼板腺功能障礙 (MGD)的治療流程

第7章 KOL的見解

第8章 未滿足需求

第9章 附錄

第10章 DelveInsight的服務內容

第11章 免責聲明

第12章 關於DelveInsight

目錄
Product Code: DIEI1068

DelveInsight's 'Meibomian Gland Dysfunction - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Meibomian Gland Dysfunction epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Meibomian Gland Dysfunction Understanding

The DelveInsight Meibomian Gland Dysfunction epidemiology report gives a thorough understanding of the Meibomian Gland Dysfunction by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Meibomian Gland Dysfunction in the US, Europe, and Japan. The report covers the detailed information of the Meibomian Gland Dysfunction epidemiology scenario in seven major countries (US, EU5, and Japan).

Meibomian Gland Dysfunction Epidemiology Perspective by DelveInsight

The Meibomian Gland Dysfunction epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Meibomian Gland Dysfunction epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Meibomian Gland Dysfunction epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Meibomian Gland Dysfunction Detailed Epidemiology Segmentation

The Meibomian Gland Dysfunction epidemiology covered in the report provides historical as well as forecasted Meibomian Gland Dysfunction epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Meibomian Gland Dysfunction report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The Meibomian Gland Dysfunction report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Meibomian Gland Dysfunction Epidemiology Report and Model provide an overview of the risk factors and global trends of Meibomian Gland Dysfunction in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Meibomian Gland Dysfunction in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Meibomian Gland Dysfunction
  • The report provides the segmentation of the Meibomian Gland Dysfunction epidemiology

Report Highlights:

  • 11-Year Forecast of Meibomian Gland Dysfunction epidemiology
  • 7MM Coverage
  • Total Cases of Meibomian Gland Dysfunction
  • Total Cases of Meibomian Gland Dysfunction according to segmentation
  • Diagnosed cases of Meibomian Gland Dysfunction

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Meibomian Gland Dysfunction?
  • What are the key findings pertaining to the Meibomian Gland Dysfunction epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Meibomian Gland Dysfunction across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Meibomian Gland Dysfunction?
  • What are the currently available treatments of Meibomian Gland Dysfunction?

Reasons to buy:

  • The Meibomian Gland Dysfunction Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Meibomian Gland Dysfunction market
  • Quantify patient populations in the global Meibomian Gland Dysfunction market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Meibomian Gland Dysfunction therapeutics in each of the markets covered
  • Understand the magnitude of Meibomian Gland Dysfunction population by its epidemiology
  • The Meibomian Gland Dysfunction Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of Meibomian Gland Dysfunction

3. Meibomian Gland Dysfunction : Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Sign and Symptoms
  • 3.3. Pathophysiology
  • 3.4. Risk Factors
  • 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

  • 5.1. Epidemiology Key Findings
  • 5.2. Assumptions and Rationale: 7MM
  • 5.3. Epidemiology Scenario: 7MM
    • 5.3.1. Meibomian Gland Dysfunction Epidemiology Scenario in the 7MM (2017- 2030)
  • 5.4. United States Epidemiology
    • 5.4.1. Meibomian Gland Dysfunction Epidemiology Scenario in the United States (2017- 2030)
  • 5.5. EU-5 Country-wise Epidemiology
    • 5.5.1. Germany Epidemiology
      • 5.5.1.1. Meibomian Gland Dysfunction Epidemiology Scenario in Germany (2017- 2030)
    • 5.5.2. France Epidemiology
      • 5.5.2.1. Meibomian Gland Dysfunction Epidemiology Scenario in France (2017- 2030)
    • 5.5.3. Italy Epidemiology
      • 5.5.3.1. Meibomian Gland Dysfunction Epidemiology Scenario in Italy (2017- 2030)
    • 5.5.4. Spain Epidemiology
      • 5.5.4.1. Meibomian Gland Dysfunction Epidemiology Scenario in Spain (2017- 2030)
    • 5.5.5. United Kingdom Epidemiology
      • 5.5.5.1. Meibomian Gland Dysfunction Epidemiology Scenario in the United Kingdom (2017-2030)
  • 5.6. Japan Epidemiology
    • 5.6.1. Meibomian Gland Dysfunction Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

  • 6.1. Meibomian Gland Dysfunction Treatment and Management
  • 6.2. Meibomian Gland Dysfunction Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report

List of Tables

  • Table 1: Meibomian Gland Dysfunction Epidemiology in 7MM (2017-2030)
  • Table 2: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Table 3: Meibomian Gland Dysfunction Epidemiology in the United States (2017-2030)
  • Table 4: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: Meibomian Gland Dysfunction Epidemiology in Germany (2017-2030)
  • Table 6: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: Meibomian Gland Dysfunction Epidemiology in France (2017-2030)
  • Table 8: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: Meibomian Gland Dysfunction Epidemiology in Italy (2017-2030)
  • Table 10: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: Meibomian Gland Dysfunction Epidemiology in Spain (2017-2030)
  • Table 12: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: Meibomian Gland Dysfunction Epidemiology in the United Kingdom (2017-2030)
  • Table 14: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Table 15: Meibomian Gland Dysfunction Epidemiology in Japan (2017-2030)
  • Table 16: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

  • Figure 1: Meibomian Gland Dysfunction Epidemiology in 7MM (2017-2030)
  • Figure 2: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Figure 3: Meibomian Gland Dysfunction Epidemiology in the United States (2017-2030)
  • Figure 4: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: Meibomian Gland Dysfunction Epidemiology in Germany (2017-2030)
  • Figure 6: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: Meibomian Gland Dysfunction Epidemiology in France (2017-2030)
  • Figure 8: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: Meibomian Gland Dysfunction Epidemiology in Italy (2017-2030)
  • Figure 10: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: Meibomian Gland Dysfunction Epidemiology in Spain (2017-2030)
  • Figure 12: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: Meibomian Gland Dysfunction Epidemiology in the United Kingdom (2017-2030)
  • Figure 14: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Figure 15: Meibomian Gland Dysfunction Epidemiology in Japan (2017-2030)
  • Figure 16: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report